original
adicciones vol. 29, nº 1 · 2017
Gender differences in success at quitting smoking:
Short- and long-term outcomes
Diferencias de género en el éxito al dejar de fumar:
resultados a corto y largo plazo
Adriana Marqueta*, Isabel Nerín*,**, Pilar Gargallo***, Asunción Beamonte***
*Tobacco Control Unit. University of Zaragoza, Spain; **Department of Medicine, Psychiatry and Dermatology. Faculty of
Medicine, University of Zaragoza, Spain; ***Department of Statistical Methods, Faculty of Economic and Business, University of
Zaragoza, Spain.
Abstract
Resumen
Smoking cessation treatments are effective in men and women.
Los tratamientos para dejar de fumar son eficaces en hombres y
However, possible sex-related differences in the outcome of these
mujeres. Sin embargo, las posibles diferencias encontradas en los
treatments remain a controversial topic. This study evaluated whether
resultados del tratamiento aún son objeto de controversia. Este estudio
there were differences between men and women in the success of
analiza si existen diferencias entre hombres y mujeres en el éxito al
smoking cessation treatment, including gender-tailored components,
dejar de fumar a corto y largo plazo (> 1 año) con un programa de
in the short and long term (> 1 year). A telephone survey was carried
tratamiento que incluye la perspectiva de género. Se realizó una
out between September 2008 and June 2009 in smokers attended
encuesta telefónica en fumadores atendidos en una unidad de
in a Smoking Cessation Clinic. All patients who have successfully
tabaquismo. Los pacientes que completaron con éxito el tratamiento
completed treatment (3 months) were surveyed by telephone
(3 meses), fueron encuestados telefónicamente para determinar
to determine their long-term abstinence. Those who remained
su abstinencia a largo plazo; se validó la abstinencia mediante
abstinent were requested to attend the Smoking Cessation Clinic for
cooximetría (CO espirado ≤10 ppm) en los que se mantenían
biochemical validation (expired CO ≤10 ppm). The probability of
abstinentes. La probabilidad de permanecer abstinentes a largo plazo
remaining abstinent in the long-term was calculated using a Kaplan-
se calculó utilizando un análisis de supervivencia de Kaplan-Meier. La
Meier survival analysis. The treatment success rate at 3-months was
tasa de éxito del tratamiento fue de 41,3% (538/1302), sin diferencias
41.3% (538/1302) with no differences by sex 89% (479/538) among
por sexo. El 89% (479/538) fue localizado por teléfono y el 47,6%
those located in the telephonic follow-up study and 47.6% (256/479)
(256/479) se mantenía abstinente sin diferencias por sexo (p = ,519);
were abstinent without differences by sex (p = .519); abstinence was
la abstinencia fue validada en 191 de 256 (53,9% hombres y 46,1%
validated with CO less than 10 ppm in 191 of the 256 (53.9% men
mujeres). En el análisis de supervivencia, la probabilidad de que
and 46.1% women). In the survival analysis, the probability of men
los hombres y las mujeres mantuvieran la abstinencia a largo plazo
and women remaining abstinent in the long-term was not significant.
no fue significativa. No hay diferencias por sexo en el resultado del
There are no differences by sex in the outcome of smoking cessation
tratamiento para dejar de fumar, que incluyan aspectos de género, a
treatment that included gender-tailored components in the short and
corto y largo plazo (> 1 año).
long term (> 1 year).
Palabras clave: Tabaquismo; cesación tabáquica; género y salud;
Keywords: Smoking; smoking cessation; gender and health; women;
mujeres; análisis de supervivencia.
survival analysis.
Received: June 2015; Accepted: January 2016
Send correspondence to:
Adriana Marqueta Baile. Pº Pamplona 4-6, 8º B. 50004. Zaragoza. Spain.
E-mail: amarqueta@cop.es
ADICCIONES, 2017 · VOL. 29 NO. 1 · PAGES. 13-21
13
Gender differences in success at quitting smoking: Short- and long-term outcomes
S
moking is the greatest public health problem in
developed countries and an emerging problem in
developing countries (López, Mathers, Ezzati, Jamison, & Murray, 2006). Worldwide, the prevalence of
smoking is higher in men than in women, although the rate
for young women is on the rise (Amos, Greaves, Nichter, &
Bloch, 2012). As a consequence of these differences in the
smoking prevalence by sex, so far the smoking related mortality has been higher among men. However, in some developed countries, the increase in the smoking habit among
women has conditioned also a rise in related mortality in
women compared with previous years. Thus, in many countries tobacco use is already a major public health concern
for women (Croghan et al., 2009; Banegas et al., 2011; US
Department of Health and Human Services, 2001).
Helping current smokers to quit is the single most important step to reduce morbidity and mortality associated with
cigarette smoking (Peto et al., 2000). Smoking cessation treatments recommended in the main clinical practice guidelines
have been found to be equally effective in men and women
(Munafo, Bradburn, Bowes, & David, 2004; Perkins & Scott,
2008). However, possible sex-related differences in the outcome of these treatments remain a controversial topic.
First, in the beginning of the 1980s, a Surgeon General’s report (US Department of Health and Human Services,1980) concluded that women had greater difficulties
in stopping smoking, although subsequent studies suggested that this conclusion was perhaps premature (Whitlock,
Vogt, Hollis, & Lichtenstein, 1997). Overall, studies which
evaluated possible differences in the results of smoking
treatment by sex showed different results. Thus, Whitlock et
al. (1997) found no gender differences in a brief clinic-based smoking intervention and Croghan et al. (2009) neither
found differences through a clinical treatment program.
Likewise, in a meta-analysis of 11 clinical trials using Nicotine Replacement Therapy (NRT) for smoking cessation
did not find gender differences between males and females
smokers (Munafo et al., 2004). Conversely, Osler, Prescott,
Godtfredsen, Hein, & Schnohr (1999) found worse results
for women in spontaneous smoking cessation whereas Piper
et al. (2010) observed that with pharmacotherapy of smoking cessation, women were less likely to quit smoking successfully than men. On the other hand, Cepeda, Reynoso,
& Erath (2004), observed that smoking abstinence between
males and females receiving NRT was mediated by intensity
of behavioural support, (with higher intensity support for
women) with poorer 1-year outcome in women vs. men, a
similar result found by Perkins et al., (2008). Finally, Scharf
& Shiffman (2004) concluded that women were less successful at quitting than men, regardless of treatment. Related to
the follow-up, numerous studies have assessed the success
of smoking cessation treatments by sex in the short and medium term (three and six months of abstinence), and even
up to one year (Croghan et al., 2009; Puente et al., 2011),
but very few have continued follow-up in the longer term,
beyond 12 months (Bjornson et al., 1995; Osler et al., 1999;
Wetter et al., 2004) also with contradictory findings.
As we can see, all these studies had many methodological
differences which could partially explain the different results: differences in the treatment applied (with or without
pharmacotherapy), different methodological criteria for
determining abstinence (self-reported or biochemical measures), or a different time length of the follow-up period. All
these differences make it difficult to draw reliable comparisons between studies.
The objective of this study was to determine whether
there were differences between men and women as regards
the success of smoking cessation treatment, in the short and
long term, with a smoking cessation program which includes gender-tailored components.
Methods
Participants
A telephone survey was carried out in smokers attended in a Smoking Cessation Clinic between 2002 and 2007
(inclusive). The participants were smokers who requested
treatment and had successfully quit at the end of the treatment. This unit is a public service that treats smokers who
request a smoking cessation treatment or are referred by
their primary care physician (general practitioner) or specialist. For access to treatment the inclusion criteria were
being a smoker older than 18 years and voluntarily agreeing
to start treatment and the exclusion criteria included having
an uncontrolled psychiatric disorder, other active drug-dependence or, in the case of women, pregnancy. All participating gave their written informed consent to be included
in the study.
Intervention
The smoking cessation program uses a group format of
60 minute sessions over the course of 3 months. The follow-up visits were arranged as follows: first session, the day
before giving up smoking; second session, the day after giving up smoking; one booster visit every week during the
first month; and at six, nine and twelve weeks of abstinence;
in summary, nine sessions over three months. All those sessions were in group format (men and women mixed) and
the day for giving up smoking was the same for all.
The smoking cessation treatment offered is a multicomponent intervention: cognitive and behavioural treatment
in group with pharmacological treatment using the medications recommended in smoking cessation treatment guidelines, such as Nicotine Replacement Therapy (NRT), Bupropion and Varenicline (Fiore et al., 2008); the fulfillment of
pharmacological treatment was carried out along the group
sessions. It is led by health professionals with extensive experience in group therapy.
ADICCIONES, 2017 · VOL. 29 NO. 1
14
Adriana Marqueta, Isabel Nerín, Pilar Gargallo, Asunción Beamonte
In the cognitive behavioural therapy, all participants received cessation counselling focused on preparing to quit,
the benefits of cessation, coping with smoking urges and
relapse prevention. Also were incorporated specific strategies for women as cognitive therapy to reduce weight/body
image concerns, how to break the link between cues and
smoking and strategies to cope with the negative affect.
Statistical analysis
A descriptive analysis was performed of the sample as a
whole, with qualitative variables expressed as absolute frequencies and the equivalent proportion of each category
and quantitative variables as means and standard deviations.
The characteristics were compared using the two sample
t-test for continuous variables and the chi-square test for categorical variables; the test used to compare short-term outcomes was the chi-square test. Two-sided p-values ≤0.05 were
used to denote statistical significance in all cases.
In the phone-based follow-up study, the abstinence time
was calculated as the number of months from the end of the
treatment to the date of the interview. A survival analysis was
performed using the Kaplan-Meier method to analyse the
probability of remaining abstinent in the long term, with
the Tarone-Ware test being used to study the possible differences in survival time between men and women (Hughes
et al., 2003; Tarone & Ware, 1977). We employed the Tarone-Ware test to asses Kaplan-Meyer plots of different groups
because this test is designed to have good power across a
wide range of survival functions. Data were analysed using
SPSS© version 15.0.
Measures
During the first visit, and before smoking cessation
treatment commenced, sociodemographics (sex, age, marital status, educational level, employment activity) and
smoking-related variables, including number of cigarettes
smoked per day, years as a smoker, number of previous
quit attempts to stop smoking (0, 1 or 2, and 3 or more)
and degree of nicotine dependence (Fagerström Test)
(Fagerström & Scheneider, 1989) were collected from all
participants. The baseline CO level was measured using a
Mini Smokerlyzer cooximeter (Bedfont Scientific Ltd., Rochester, UK) (Jarvis, Russell, & Saloojee, 1980). Finally, a
medical history (hypertension, cholesterol levels, cardiovascular disease, hyper- or hypothyroidism and cancer) was
completed. Subjects were also asked about their previous
history of anxiety and/or depression requiring pharmacological treatment. This information was collected using two
variables: history of depression before the smoking cessation treatment, or during treatment. In this first visit the
pharmacological treatment was prescribed according to individual profile of each smoker.
Continuous abstinence, in other words not smoking from
the quit day until the end of the treatment (3 months), as
validated by CO values of ≤ 10 ppm, was considered to indicate successful treatment. Expired-air CO was assessed at
each of the follow-up visits. As the intention-to-treat criterion was used to assess the success percentage, the success
rate was taken to be the proportion of abstinent subjects
(continuous and CO validated abstinence) with respect to
the total number of subjects who started treatment. Both
these criteria (success and success rate) were established on
the basis of the recommendations to communicate the outcome of smoking cessation treatment (Hughes et al., 2003).
All subjects who failed to attend the final group treatment
session (week 12) were considered to be smokers.
Results
A total of 1472 people, 768 men (52.2%) and 704 women (47.8%), completed a medical history. The mean age
was 43.2 (SD = 10.3) years. Of these, 170 (11.5%) decided
not to commence smoking cessation treatment, 90 (52.9%)
men and 80 (47.1%) women. All subjects who decided not
to start smoking cessation treatment (170) were excluded
from the study and were therefore not included in the subsequent analyses.
The sample studied included 1302 people of whom 678
(52.1%) were male and 624 (47.9%) female. The mean age
was 43.4 (SD = 10.2) years. The characteristics of the sample as a whole, and the male and female subgroups, can be
found in Table 1. On average, male subjects were older than
females (44.2 vs. 42.5 years) and were more likely to be married (73.6% vs. 58.8%), be working (87.9% vs. 77.6%), and
to have a secondary education (47.3% vs. 38.9%), whereas
women were more likely to have completed higher education (41.7% vs. 27.3% for men). As far as the smoking-related variables are concerned, men smoked more cigarettes
per day than women (26.7 vs. 23.7), had been smoking for
longer (27.9 vs. 24.9 years), had higher levels of CO (29.3
vs. 24.9) and 56.6% had attempted to stop smoking once or
twice compared with 49.1% of women. All these differences
were statistically significant (p<0.05).
Despite the different consumption patterns, no statistically significant differences were found between the sexes
in terms of nicotine dependence (6.3 vs. 6.2 points; p=.431).
Analysis of the different diseases studied showed that men
were more likely to present cardiovascular risk factors such
Follow-up
To analyze long-term abstinence (>1 year), a telephone
survey of all subjects who were abstinent at the end of treatment (3 months) was carried out between September 2008
and June 2009. Trained interviewers called each subject a
maximum of five times in two different time periods. As
follow-up was phone-based, those subjects who reported
not to have smoked again since receiving treatment were
asked to attend the unit for biochemical validation of their
abstinence.
ADICCIONES, 2017 · VOL. 29 NO. 1
15
Gender differences in success at quitting smoking: Short- and long-term outcomes
Table 1. Characteristics of the patients who initiated smoking cessation treatment (2002-2007) (N=1302)
Total
% (N)
Men
% (N)
Women
% (N)
p
43.4 (10.2)
44.2 (10.4)
42.5 (9.9)
.002
Sociodemographic
Age (SD)
Marital status %(N)
< .0001
Single
23.5 (306)
20.1 (136)
27.3 (170)
Divorced or widowed
10.0 (130)
6.3 (43)
13.9 (87)
Married
66.5 (866)
73.6 (499)
58.8 (367)
Educational level %(N)
< .0001
Basic
22.5 (293)
25.4 (172)
19.4 (121)
Secondary
43.3 (564)
47.3 (321)
38.9 (243)
Higher
34.2 (445)
27.3 (185)
41.7 (260)
Employment %(N)
< .0001
Not active
17.1 (222)
12.1 (82)
22.4 (140)
Working
82.9 (1080)
87.9 (596)
77.6 (484)
No. cigarettes/day (SD)
25.3 (10.4)
26.7 (11.5)
23.7 (8.9)
< .0001
Years smoking (SD)
26.4 (10.1)
27.9 (10.7)
24.9 (14.8)
.003
Consumption pattern
Previous attempts %(N)
0
.019
26.5 (345)
23.9 (162)
29.3 (183)
53 (690)
56.6 (384)
49.1 (306)
3 or more
20.5 (267)
19.5 (132)
21.6 (135)
Fagerström Test (SD)
6.2 (2.2)
6.3 (2.2)
6.2 (2.2)
.431
27.2 (15.8)
29.3 (16.4)
24.9 (14.8)
.003
1-2
Baseline CO (SD)
Medication prescribed %(N)
.007
None
0.2 (2)
0.1 (1)
0.2 (1)
Nicotine replacement therapy
64.8 (844)
69.0 (468)
60.3 (376)
Bupropion
31.1 (405)
27.9 (189)
34.6 (216)
Varenicline
3.9 (51)
2.9 (20)
5.0 (31)
Hypertension
10.2 (133)
12.1 (82)
8.2 (51)
.020
Cholesterol
9.8 (127)
12.7 (86)
6.6 (41)
< .0001
Cardiovascular
8.4 (109)
11.2 (76)
5.3 (33)
< .0001
Diabetes
3.5 (46)
4.9 (33)
2.1 (13)
.007
Hypo/Hyperthyroidism
3.1 (41)
0.7 (5)
5.8 (36)
< .0001
Cancer
1.5 (19)
0.9 (6)
2.1 (13)
.072
Anxiety or depression before treatment %(N)
35.7 (465)
24.5 (166)
47.9 (299)
< .0001
Anxiety or depression during treatment %(N)
10.4 (136)
5.9 (40)
15.4 (96)
< .0001
Diseases %(N)
p ≤ ,05
ADICCIONES, 2017 · VOL. 29 NO. 1
16
Adriana Marqueta, Isabel Nerín, Pilar Gargallo, Asunción Beamonte
as hypertension, cholesterol and diabetes. In contrast, women were more likely to present a psychiatric-type disorder
such as anxiety and/or depression requiring pharmacological treatment, either at the beginning of treatment or previously.
The three-month treatment success rate using the intention-to-treat criterion was 41.3% (538/1302). There were
no statistically significant differences in success rate by sex,
although the percentage of abstainers was higher for men
than for women [43.8% (297/678) vs. 38.6% (241/624) respectively; p=.058].
A total of 479 of the 538 subjects who successfully completed the treatment were located during the phone-based
follow-up study. Of the 59 who did not reply, 24 had changed phone number, 21 could not be located in the stipulated number of attempts, eight refused to respond to the
questionnaire and six had died. Phone-based follow-up was
therefore performed with 89% (479/538) of those subjects who successfully completed treatment, 47.6% (256) of
whom had remained abstinent since the day they stopped
smoking (the quit day); therefore it was 19.6% with respect to the total number of subjects who started treatment
(256/1302). There were no statistically significant differences by sex (p=.519). Abstinence was validated in 191 (53.9%
men and 46.1% women) of the 256 subjects who claimed to
have stopped smoking, with CO values of less than 10 ppm;
abstinence could not be validated in the remainder (65) as
they failed to keep their appointment (see Figure 1).
When compared using the Tarone-Ware test, the differences detected in the survival analysis used to determine
the probability of men and women remaining abstinent in
the long-term were not significant (see Figure 2).
Figure 1. Study scheme
People requesting treatment 2002–2007
N=1472
768 (52.2%) male and 704 (47.8%) female
Did not start treatment
N=170 (11.5%)
Started treatment
N=1302
678 (52.1%) male and 624 (47.9%) female
Abstinence at 3 months
N=538 (41.3%)
297 (55.2%) male and 241 (44.8%) female
Telephone survey
N=538
Did not reply N=59 (11%)
Replied
N=479 (89%)
Smoking N=223 (41.4%)
Not smoking
N=256 (47.6%)
143 (55.9%) male and 113 (44.1%) female
Scheduled for CO
N=201
110 (54.7%) male and 91 (45.3%) female
Discussion
Our results show that there are no gender differences
in the short- and long-term success of smoking cessation
treatment which includes gender-tailored components,
with men and women having the same probability of remaining abstinent. However, we found sex-based differences in
the sociodemographic variables of those people who commenced treatment in our unit. Thus, women tended to be
younger, but were less likely to be married than men; these
differences are similar to those described by other authors
(Croghan et al., 2009; Ramon, Bruguera, Fernández, Sanz
de Burgoa, & Ramírez, 2009). The higher percentage of
working males reflects the general situation in Spain, where
the employment rate for men is higher. Our study also highlights the predominance of women with higher educational qualifications with respect to the greater proportion of
men with a secondary education, also found by Iliceto, Fino,
Pasquariello, D´Angelo Di Paola, & Enea (2013) in Italy recently. This aspect corresponds, for women, with phase III
of the epidemiological model proposed by López, Collishow
Attended
N=191 (35.5%)
103 (53.9%) male and 88 (46.1%) female
& Piha (1994) and recently review by Thun, Peto, Boreham
& Lopez (2012) in which countries like Spain or Italy are currently placed, whereby women with more educational qualifications tend to start smoking first but also decide to stop
smoking first. Concerning the high number of women who
requested treatment, other studies carried out in a similar
setting (Smoking cessation Units) also showed high number
of women, most of them with high educational level (Croghan et al., 2009; Fernández et al., 2006; Fidler, Ferguson,
Brown, Stapleton & West, 2013)
In accordance with previous findings from our group
(Marqueta, Nerín, Jiménez-Muro, Gargallo & Beamonte,
ADICCIONES, 2017 · VOL. 29 NO. 1
17
Gender differences in success at quitting smoking: Short- and long-term outcomes
ceto et al., 2013; Swan, Ward, Carmelli, & Jack, 1993). The
reasons used to justify the worse outcome of smoking cessation treatments in women include the suggestion that women perceive the act of smoking as a strategy to reduce negative affects (for example stress) and/or increase positive
ones (Xu et al., 2008). It is well known that women smoke
for different reasons than men, for example to reduce negative states (sadness, anxiety, etc.), and that they have different worries when stopping smoking, such as weight control and the appearance of depressive symptoms (Croghan
et al., 2009; US Department of Health and Human Services,
2001; WHO, 2001); Therefore, it has been suggested that
in women smoking behaviour might be more influenced
by behavioural components and less by the nicotine dependence than in men, and accordingly the treatment should
be appropriately tailored to women to increase their chances of abstinence (Bohadana et al., 2003). Some studies
observed that the result in women of smoking cessation
program was mediated by intensity of behavioural support,
with higher intensity support for women, but they did not
include any specific recommendation for women (Cepeda
et al., 2004). In our study, we included strategies to prevent
relapses that are specific to women, such as weight aspects,
facing up to negative situations and how to handle stress,
which could explain the lack of a difference between men
and women as regards the outcome of smoking cessation
treatment.
Moreover, Croghan et al. (2009), adjusting for the baseline characteristics of smokers, observed that the likelihood
of abstinence did not differ by sex and suggested that observed differences in tobacco abstinence outcomes between
female and male smokers may be explained by other characteristics (e.g., baseline smoking rate, history of depression
etc.), which are different for women and men. In the same
way, our group, using a similar methodology, found no differences in the outcome of smoking cessation programs by sex
suggesting that the predictors of successful abstinence are
different for females and males (Marqueta et al., 2013). In
other words and as others authors have suggested previously
the rate of success in smoking cessation is similar for both sexes, but the process for men and women is different (Whitlock et al., 1997). These findings support the importance
of individualizing the treatment for smokers, depending on
being a smoker woman or a smoker man.
In our study the long term success can be seen in Figure 1, and in agreement with the findings of Chatkin et al.
(2006), men and women have the same probability of remaining abstinent in the long term. Knowing long term results
highlights that men and women have the same success after
undergoing a smoking cessation program, including gender-tailored components, and is consistent with the short
term findings.
As limitations of our study, it should be noted that the
study population is not representative of the general smoker
Figure 2. Long-term abstinence by sex
Male
Abstinence rate
Female
Follow-up (months)
2013) and from other authors in recent studies (Chatkin et
al. 2006; Iliceto et al. 2013), no statistically significant differences between men and women were found in terms of the
degree of nicotine dependence measured by Fagerström
Test. This “equality” reflects the increased consumption in
women over the past few years and is in contrast to literature
reports from the 1990s, which found a lower dependence
in women (Bjornson et al., 1995; Ward, Klesges, Zbikowski,
Bliss, & Garvey, 1997). Furthermore, this study was undertaken in a specialised Smoking Cessation Clinic where the
men and women who request treatment are usually smokers
with a moderate to severe dependence.
Our analysis of reported diseases shows that, in accordance with previous studies (Killen, Fortmann, Varady, & Kraemer, 2002; Marqueta, Jiménez-Muro, Beamonte, Gargallo,
& Nerín 2010), anxiety disorders and/or depression are
more common in women, whereas a larger proportion of
men present cardiovascular risk factors. Both these aspects
have been reported in the general non-smoking population
and may be due to gender differences arising from both psychosocial and hormonal effects (Borrell, García-Calvente,
& Martí-Boscà, 2004; National Institute of Mental Health,
2009).
Concerning the success of the treatment of smoking cessation, although the success rate was higher in men than
women we have found no short-term gender differences in
the same way as other studies (Croghan et al., 2009; Killen
et al., 2002; Puente et al., 2011; Raich et al., 2015; Whitlock
et al., 1997;), whereas other authors, such as Bohadana, Nilsson, Rasmussen & Martinet, (2003), Wetter et al., (2004)
and Bjornson et al., (1995), have found higher success rates
in men and a higher probability of relapse in women (Ili-
ADICCIONES, 2017 · VOL. 29 NO. 1
18
Adriana Marqueta, Isabel Nerín, Pilar Gargallo, Asunción Beamonte
Conflicts of interests
population as it only includes smokers who requested treatment in a specialised Smoking Cessation Clinic. Despite
this, the sample of smokers is sufficiently large to allow the
differences between men and women in terms of treatment
success to be analysed and is therefore appropriate for the
proposed objective. Besides, the studies carried out in Smoking Cessation Units usually analyze all patients treated and
they do not use samples (Fernandez et al., 2006). Another
limitation of our study could be the number of patients who
said at the telephone survey that they were not smoker and
did not attend to the biochemical validation (see figure 1).
However, this situation is very common in studies which evaluate long term abstinence, where these patients are considered as smokers (Álvarez et al., 2015); this criterion was
also applied in our study.
On the other hand, one of the strengths of the study is
the large and clinical sample and the long-term follow-up assessment, unlike most other studies which tend to be clinical
trials with shorter follow-up periods. Furthermore, we use
continuous abstinence which is the most rigorous measure
and considered by many to be the gold standard, since it
requires a longer period of abstinence than other measures
and thus is more likely to represent long-term abstinence;
and we validated abstinence with CO. Also, according to the
intention-to-treat criterion applied to assess the success percentage, all subjects who failed to attend were considered
as smokers. Similarly, and as is recommended by the SRNT
(2002) (Hughes et al., 2003), we used a survival analysis
using the Kaplan-Meier method to analyse the probability of
remaining abstinent in the long term. This method provides
more detailed information than a simple cut-off point rate
as it reflects the evolution in time and provides probability information, thereby more accurately reflecting the patient´s actual situation. Since smoking is not a static process
in time (Prochaska & DiClemente, 1983), it appears more
appropriate to use dynamic techniques, such as survival
analysis, to assess such outcomes. In contrast, many studies
evaluate the abstinence only with self-declaration in a sample cut-off point.
In summary, our study shows that there are no differences by sex in terms of the outcome of smoking cessation
treatment when following the treatment recommended in
clinical practice guidelines. These recommendations include tailoring the treatment on the basis of each smoker’s
characteristics. This means that is necessary to adapt smoking cessation treatment taking into account the different
worries and needs for women and men.
The authors declare that there are no conflicts of interests.
References
Álvarez, F.J., Ferrer, M., Ruiz, A., Medina, J.F., Romero,
B., Sáez, A., & Romero, A. (2015). Predictors of 10-year
smoking abstinence in smokers abstinent for 1 year
after treatment. Addiction, 111, 545-551. doi: 10.1111/
add.13220
Amos, A., Greaves, L., Nichter, M., & Bloch, M. (2012). Women and tobacco: a call for including gender in tobacco
control research, policy and practice. Tobacco Control, 21,
236-243. doi: 10.1136/tobaccocontrol-2011-050280.
Banegas, J.R., Díez-Gañán, L., Bañuelos-Marco, B., González-Enríquez, J., Villar-Álvarez, F., Martín-Moreno, J.M.,
…Jiménez-Ruiz, C. (2011). Smoking-attributable deaths
in Spain. Medicina Clínica, 136, 97-102. doi: 10.1016/j.
medcli.2010.03.039.
Bjornson, W., Rand, C., Connett, J.E., Lindgren, P., Nides,
M., Pope, F., …O´Hara, P. (1995). Gender differences
in Smoking Cessation after 3 Years in the Lung Health
Study. American Journal of Public Health, 85, 223-230.
Bohadana, A., Nilsson, F., Rasmussen, T., & Martinet, Y.
(2003). Gender differences in quit rates following smoking cessation with combination nicotine therapy: Influence of baseline smoking behavior. Nicotine & Tobacco
Research, 5, 111-116.
Borrell, C., García-Calvente, M. M., & Martí-Boscà, J.V.
(2004). La salud pública desde la perspectiva de género
y clase social. Gaceta Sanitaria, 18,2-6.
Chatkin, J.M., Abreu, C.M., Blanco, D.C., Tonietto, R.,
Scaglia, N., Wagner, M.B., & Fritscher, C.C. (2006). No
gender difference in effectiveness of smoking cessation
treatment in a Brazilian real-life setting. The International
Journal of Tuberculosis and Lung Disease, 10, 499-503.
Cepeda, A., Reynoso, J.T., & Erath, S. (2004). Meta-Analysis of the Efficacy of Nicotine Replacement Therapy
for Smoking Cessation: Differences Between Men and
Women. Journal of Consulting and Clinical Psychology, 72,
712-722.
Croghan, I.T., Ebbert, J.O., Hurt, R.D., Hays, J.T., Dale, L.C.
Warner, N. & Schoroeder, D.R. (2009). Gender differences among smokers receiving interventions for tobacco
dependence in a medical setting. Addictive Behaviors, 34,
61-67. doi: 10.1016/j.addbeh.2008.08.010.
Fagerstrom, K.O. & Schneider, N.G. (1989). Measuring
nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. Journal of Behavioral Medicine, 12,
159-182.
Fernandez, E., Schiaffino, A., Borrell, C., Benach, J., Ariza,
C., Ramon, J.M., …Kunst, A. (2006). Social class, education, and smoking cessation: Long-term follow-up of
Acknowledgements
This work has been financed by Grupo de Investigación
en Tabaquismo B86, del Gobierno de Aragón, (Spain) and
by Ministerio de Ciencia e Innovación. Subprograma de Acciones Complementarias, (Ref: PSI2008-05177-E) (Spain).
ADICCIONES, 2017 · VOL. 29 NO. 1
19
Gender differences in success at quitting smoking: Short- and long-term outcomes
patients treated at a smoking cessation unit. Nicotine &
Tobacco Research, 8, 29-36.
Fidler, J., Ferguson, S.G., Brown, J., Stapleton, J., & West,
R. (2013). How does rate of smoking cessation vary by
age, gender and social grade? Findings from a population survey in England. Addiction, 108, 1680-1685. doi:
10.1111/add.12241.
Fiore, M.C., Jaen, C.R., Baker, T.B., Baikey, W.C., Benowitz,
N.L., Curry, S.J., ...Wewers, M.E. (2008). Treating tobacco use and dependence. A report of the US Surgeon General
Rockville, MD: U.S. Department of Health and Human
Services, Public Health Service, 257p.
Hughes, J.R., Keely, J.P., Niaura, R.S., Ossip-Klein, D.J.,
Richmond, R.L, & Swan, G.E. (2003). Measures of abstinence in clinical trials: issues and recommendations.
Nicotine & Tobacco Research, 5, 13-25.
Iliceto, P., Fino, E., Pasquariello, S., D´Angelo Di Paola,
M.E., & Enea, D. (2013). Predictors of success in smoking cessation among Italian adults motivated to quit.
Journal of Substance Abuse Treatment, 44, 534-540. doi:
10.1016/j.jsat.2012.12.004.
Jarvis, M.J., Russell, M.A., & Saloojee, Y. (1980). Expired
air carbon monoxide: a simple breath test of tobacco
smoke intake. British Medical Journal, 281, 484-485.
Killen, J.D., Fortmann, S.P., Varady, A., & Kraemer, H.C.
(2002). Do Men Outperform Women in Smoking Cessation Trials? Maybe, But Not by Much. Experimental and
Clinical Psychopharmacology, 10, 295-301.
López, A.D., Collishow, H.E., & Piha, T. (1994). A descriptive model of the cigarette epidemic in developed countries. Tobacco Control, 3, 242-247.
López, A.D., Mathers, C.D., Ezzati, M., Jamison, D.T., &
Murray, C.J. (2006). Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet, 367, 1747-1757.
Marqueta, A., Nerín, I., Jiménez-Muro, A., Gargallo, P.,
& Beamonte, A. (2013). Factores predictores de éxito
según género en el tratamiento del tabaquismo. Gaceta
Sanitaria, 27, 26-31. doi: 10.1016/j.gaceta.2011.12.011
Marqueta, A., Jiménez-Muro, A., Beamonte, A., Gargallo,
P., & Nerín, I. (2010). Evolución de la ansiedad en el
proceso de dejar de fumar en fumadores que acuden
a una Unidad de Tabaquismo. Adicciones, 22, 317-324.
Munafo, M., Bradburn, M., Bowes, L., & David, S. (2004).
Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis. Nicotine
& Tobacco Research, 6, 769-776.
National Institute of Mental Health, 2009. Women and depression. Retrieved from: http://www.nimh.nih.gov/
health/publications/women-and-depression-discovering-hope/depression-what-every-woman-should-know.
pdf
Osler, M., Prescott, E., Godtfredsen, N., Hein, H.O., & Schnohr, P. (1999). Gender and determinants of smoking
cessation: a longitudinal study. Preventive Medicine, 29,
57-62.
Perkins, K.A. & Scott, J. (2008). Sex differences in longterm smoking cessation rates due to nicotine patch.
Nicotine & Tobacco Research, 10, 1245-1251. doi:
10.1080/14622200802097506.
Peto, R., Darby, S., Deo, H., Silcocks, P., Whitley, E., & Doll,
R. (2000). Smoking, smoking cessation, and lung cancer
in the UK since 1950: combination of national statistics
with two case-control studies. British Medical Journal, 321,
323-329.
Piper, M.E., Cook, J.W., Schlam, T.R., Jorenby, D.E., Smith, S.S., Bolt, D.M., & Loh, WY. (2010). Gender, race,
and education differences in abstinence rates among
participants in two randomized smoking cessation trials.
Nicotine & Tobacco Research, 12, 647-657. doi: 10.1093/
ntr/ntq067.
Prochaska, J.O. & DiClemente, C.C. (1983). Stages and
processes of self change of smoking: toward an integrative model of change. Journal of Consulting and Clinical
Psychology, 51, 390-395.
Puente, D., Cabezas, C., Rodriguez-Blanco, T., Fernández-Alonso, C., Cebrian, T., Torrecilla, M.,…& Martín,
C. (2011). The role of gender in a smoking cessation
intervention: a cluster randomized clinical trial. BMC
Public Health, 11, 369. doi: 10.1186/1471-2458-11-369.
Raich. A., Martínez-Sánchez, J.M., Marquilles, E., Rubio,
L., Fu, M., & Fernández, E. (2015). Smoking cessation
after 12 months with multi-component therapy. Adicciones, 27, 37-46.
Ramon, J.M., Bruguera, E., Fernández, C., Sanz de Burgoa,
V., & Ramírez, E. (2009). Motivos para dejar de fumar en
España en función del sexo y la edad. Gaceta Sanitaria,
23, 539.e1-539.e6. doi: 10.1016/j.gaceta.2009.07.004.
Scharf, D. & Shiffman, S. (2004). Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of Bupropion SR. Addiction, 99, 1462-1469.
SRNT Subcommittee on Biochemical Verification. (2002).
Biochemical verification of tobacco use and cessation.
Nicotine & Tobacco Research, 4, 149-159.
Swan, G.E., Ward, M.M., Carmelli, D., & Jack, L.M. (1993).
Differential rates of relapse in subgroups of male and
female smokers. Journal of Clinical Epidemiology, 46, 10411053.
Tarone, R.E. & Ware, J. (1977). On distribution-free tests for
equality of survival distributions. Biometrika 64, 156-160.
Thun, M., Peto, R., Boreham, J., & Lopez, A.D. (2012).
Stages of the cigarette epidemic on entering its second
century. Tobacco Control, 21, 96-101. doi: 10.1136/tobaccocontrol-2011-050294.
US Department of Health and Human Services (USDHHS) (2001). Women and Smoking: A report of the Surgeon
ADICCIONES, 2017 · VOL. 29 NO. 1
20
Adriana Marqueta, Isabel Nerín, Pilar Gargallo, Asunción Beamonte
General. Rockville, MD. Public Health Service, Office of
the surgeon General.
US Department of Health and Human Services (USDHHS) (1980). The health consequences of smoking for women. A report of the Surgeon General. Rockville, MD. Public
Health Service, Office of the surgeon General.
Ward, K., Klesges, R.C, Zbikowski, S.M., Bliss, R.E., & Garvey, A.J. (1997). Gender differences in the outcome of a
unaided smoking cessation attempt. Addictive Behaviors,
22, 521-533.
Wetter, D.W., Cofta-Gunn, L., Fouladi, R.T., Cinciripini,
P.M, Sui, D., & Gritz, E. (2004). Late relapse/sustained
abstinence among former smokers: a longitudinal study.
Preventive Medicine, 39, 1156-1163.
Whitlock, E.P., Vogt, M.T., Hollis, J.F., & Lichtenstein, E.
(1997) Does gender affect response to a brief clinic-based smoking intervention? American Journal of Preventive
Medicine, 13, 159-166.
World Health Organization. Women and the tobacco epidemic. Challenges for the 21st century. Geneva: WHO, 2001.
Retrieved from:http://whqlibdoc.who.int/hq/2001/
WHO_NMH_TFI_01.1.pdf
Xu, J., Azizian, A., Monterosso, J., Domier, C.P., Brody, A.L.,
Fong, T.W., & London, E.D. (2008). Gender effects on
mood and cigarette craving during early abstinence and
resumption of smoking. Nicotine & Tobacco Research, 10,
1653-1661. doi: 10.1080/14622200802412929.
ADICCIONES, 2017 · VOL. 29 NO. 1
21